Skip to main content

Table 1 The effect of WAY100635, prazosin or clonidine on the striatal dopamine, DOPAC and HVA

From: Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson’s disease

 

Dopamine

DOPAC

HVA

Turnover rate

Vehicle

19.49 ± 0.75**

1.62 ± 0.12**

1.03 ± 0.04**

0.14 ± 0.01

WAY100635 (0.05 mg/kg)

18.22 ± 1.21**

1.73 ± 0.09**

0.91 ± 0.04**

0.15 ± 0.01

prazosin (0.03 mg/kg)

20.27 ± 2.33**

1.51 ± 0.14**

0.79 ± 0.09**

0.12 ± 0.01#

clonidine (0.15 mg/kg)

22.76 ± 1.88**

1.47 ± 0.07**

0.84 ± 0.05**

0.10 ± 0.01##

MPTP

3.38 ± 0.35

0.51 ± 0.05

0.44 ± 0.04

0.28 ± 0.01##

MPTP + mirtazapine (16 mg/kg)

1.90 ± 1.21

0.38 ± 0.08

0.29 ± 0.06

0.78 ± 0.25*

MPTP + mirtazapine (16 mg/kg) + WAY100635 (0.05 mg/kg)

2.25 ± 0.47

0.40 ± 0.10

0.32 ± 0.08

0.33 ± 0.05

MPTP + mirtazapine (16 mg/kg) + prazosin (0.03 mg/kg)

3.49 ± 0.48

0.56 ± 0.04

0.37 ± 0.01

0.28 ± 0.03

MPTP + mirtazapine (16 mg/kg) + clonidine (0.15 mg/kg)

2.90 ± 0.68

0.58 ± 0.68

0.45 ± 0.07

0.31 ± 0.04

  1. The results are shown as the mean (μg/g tissue) ± SEM of 4–6 animals/group. Statistical significance was evaluated by Student-Newman-Keuls test (F(DA) 8,40 = 84.267, F(DOPAC) 8,40 = 32.896, F(HVA) 8,40 = 29.578, F(Turnover) 8,40 = 4.232, *P < 0.05,**P < 0.01 compared with MPTP-treated group and P < 0.05 compared with MPTP + mirtazapine group), or by Student’s t-test (#P < 0.05, ##P < 0.01 compared with vehicle group).